Engaging stakeholders along health technology assessment pathways: A scoping review of international practice

Simple item page
dc.contributor.authorCarter, D.
dc.contributor.authorHASSAN, M.
dc.contributor.authorGao, Y.
dc.contributor.authorChoi, O.
dc.contributor.authorTamblyn, D.
dc.contributor.authorMerlin, T.
dc.date.issued2025
dc.descriptionPublished online 30 September 2025
dc.description.abstractObjectives: Health technology assessment (HTA) has been characterized as a complex adaptive system that centrally features stakeholder interactions. This article provides an overview of current practices in HTA stakeholder engagement concerning medicines. Methods: We conducted a scoping review of English-language sources published between 2018 and 2023, including 66 peer-reviewed articles and 264 gray literature sources describing stakeholder involvement in HTA processes relating to medicines. Results: Industry is commonly permitted to provide a submission for funding, though the modes and time points of industry engagement are many. Clinician and patient engagement are regarded as especially important with increased intervention complexity and innovation. Stakeholder engagement is perhaps mostly conducted to enhance the collation and interpretation of evidence, not necessarily to increase the legitimacy of the HTA process or give stakeholders influence over a decision that affects them. Patients are mostly engaged through broader public consultation. Sometimes they work directly with other stakeholders. Problems with patient engagement include challenges with recruitment, time, and resource constraints. Stakeholder groups can also differ in how they view and prioritize public and patient engagement. Public engagement is often limited to a matter of transparency and public accountability, but the reasons to undertake public engagement are numerous and varied. They include gaining input on affordability or prioritization issues. Conclusions: HTA decision-making committees should commit to publicly communicating how they considered and made use of various stakeholder inputs. This could build trust and confidence in the committees and guide the public and patients on the information that committees find helpful.
dc.description.statementofresponsibilityDrew Carter, Mah Laka, Yuan Gao, Olivia Choi, David Tamblyn, and Tracy Merlin
dc.identifier.citationInternational Journal of Technology Assessment in Health Care, 2025; 41(1):e69-1-e69-9
dc.identifier.doi10.1017/S0266462325100494
dc.identifier.issn0266-4623
dc.identifier.issn1471-6348
dc.identifier.orcidCarter, D. [0000-0002-1221-6656]
dc.identifier.orcidGao, Y. [0000-0001-6647-2156]
dc.identifier.orcidTamblyn, D. [0000-0002-6382-3886]
dc.identifier.orcidMerlin, T. [0000-0002-7293-4262]
dc.identifier.urihttps://hdl.handle.net/2440/148052
dc.language.isoen
dc.publisherCambridge University Press
dc.rights© Crown Copyright - The University of Adelaide, 2025. Published by Cambridge University Press. This is an Open Access article, distributed under the terms of the Creative Commons Attribution- NonCommercial-ShareAlike licence (http:// creativecommons.org/licenses/by-nc-sa/4.0), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the same Creative Commons licence is used to distribute the re-used or adapted article and the original article is properly cited. The written permission of Cambridge University Press must be obtained prior to any commercial use.
dc.source.urihttps://doi.org/10.1017/S0266462325100494
dc.subjectevidence-based medicine; patient participation; stakeholder participation; technology assessment; biomedical; social responsibility
dc.titleEngaging stakeholders along health technology assessment pathways: A scoping review of international practice
dc.typeJournal article
pubs.publication-statusPublished

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
hdl_148052.pdf
Size:
8.78 MB
Format:
Adobe Portable Document Format
Description:
Published version
Download

Collections

Research Outputs